Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

類似資料

• Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
  著者:: Parra, H S, 等
  出版事項: (2004)
• Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
  著者:: Nutt, J E, 等
  出版事項: (2004)
• Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
  著者:: Okubo, S, 等
  出版事項: (2004)
• The effect of ZD1839 (Iressa(TM)), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC‐15 cells
  著者:: Al‐Hazzaa, A., 等
  出版事項: (2005)
• Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects
  著者:: Azzariti, Amalia, 等
  出版事項: (2006)